Description of Medical ServiceThis service is for use of optical coherence tomography in the diagnosis and monitoring of treatment with ranibizumab in patients with retinal vein occlusion.
Description of Medical ConditionRVO is the second most sight-threatening retinal vascular disease after diabetic retinopathy. If untreated, RVO does not resolve in the majority of patients but results in visual impairment and significant ocular complications. RVO is not a chronic condition; it is an acute event that causes reduced retinal perfusion, retinal ischaemia and increased production of vascular endothelial growth factor (VEGF). Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) and is considered a treatment option.
Reason for ApplicationNew MBS item
Medical Service TypeCo-dependent technology
Previous Application NumberNot Applicable
Public Summary DocumentOCT PSD - Assessment of investigative medical services for monitoring - July 2015(PDF 535 KB)
OCT PSD - Assessment of investigative medical services for monitoring - July 2015 (Word 63 KB)